John L.
Sorensen
a,
Karine
Auclair
b,
Jonathan
Kennedy
c,
C.
Richard Hutchinson
c and
John C.
Vederas
*a
aDepartment of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada. E-mail: john.vederas@ualberta.ca; Fax: 00 1 780 492 5475; Tel: 00 1 780 492 8231
bDepartment of Chemistry, McGill University, 801 Sherbrooke Street West, Montreal, Quebec H3A 2K6, Canada. E-mail: karine.auclair@mcgill.ca; Fax: 00 1 514 398 3797; Tel: 00 1 514 398 2822
cKosan Biosciences Inc., 3832 Bay Center Place, Hayward, California 94545, USA. E-mail: hutchinson@kosan.com; Fax: 00 1 510 732 8401; Tel: 00 1 510 732 8400
First published on 21st November 2002
Two mutants of Aspergillus terreus with either the lovC or lovA genes disrupted were examined for their ability to transform nonaketides into lovastatin 1, a cholesterol-lowering drug. The lovC disruptant was able to efficiently convert dihydromonacolin L 5 or monacolin J 9 into 1, and could also transform desmethylmonacolin J 15 into compactin 3. In contrast, the lovA mutant has an unexpectedly active β-oxidation system and gives only small amounts of 1 upon addition of the immediate precursor 9, with most of the added nonaketide being degraded to heptaketide 22. Similarly, the lovA mutant does not accumulate the polyketide synthase product 5 and rapidly degrades any 5 added as a precursor via two cycles of β-oxidation and hydroxylation at C-6 to give 20. The possible involvement of epoxides 21a and 21b in the biosynthesis of 1 was also examined, but their instability in fermentation media and fungal cells will require purified enzymes to establish their role.
Biosynthetic studies on lovastatin 1 with fungi, such as Aspergillus terreus, show that its assembly via a polyketide pathway involves intial construction of dihydromonacolin L 5. The cooperation of polyketide synthases (PKSs) encoded by the lovB and lovC genes (Fig. 1) accomplish the ca. 35 steps necessary to generate 5 (Scheme 1).5,6 In the absence of the LovC protein, which imparts enoyl reductase activity to the complex, the LovB iterative type I PKS enzyme generates truncated pyranones 6 and 7.5 During normal biosynthesis, oxidative transformations of the PKS product 5 introduce a second double bond in the decalin (decahydronaphthalene) system and add the C-8 hydroxyl to form monacolin J 9.7 The 2-methylbutyryl side chain is produced by a separate PKS encoded by lovF, and further used by LovD to directly acylate 9 and yield 1.5 The function of LovA, a protein essential for the formation of 1, is not fully understood, but it has sequence homology to P450 enzymes and is probably involved in the oxidative conversion of 5 to introduce the diene system present in 9. Biosynthetic studies on compactin 3 using the fungus Penicillium aurantiogriseum indicate a labelling pattern analogous to that seen in lovastatin 1,8a but the genetic machinery required for the formation of 3 has not yet been reported.†
![]() | ||
Fig. 1 Lovastatin biosynthesis genes. |
![]() | ||
Scheme 1 Biosynthesis of Lovastatin. |
Preliminary studies using an A. terreus mutant with the lovC gene disrupted demonstrated that cyclic nonaketide precursors such as dihydromonacolin L 5 and monacolin J 9 could be transformed to lovastatin 1 by this organism.9 We now report full details of this work as well as transformations of other cyclic nonaketides by this mutant and by an A. terreus mutant having a disrupted lovA gene. The results suggest that gene disruption can alter the profile of secondary metabolites in ways that cannot be easily predicted based solely on their function in a biosynthetic pathway.
![]() | ||
Fig. 2 Crystal structure of 5 (top) and 21a (bottom). |
The specificity of the late stage enzymes was probed by examining whether 6-desmethylmonacolin J 15 could be transformed into compactin 3 by the A. terreus lovC mutant. When 15 (obtained by the basic hydrolysis of 3) was added to fermentation cultures of this mutant, 3 was isolated from the culture broth in 45% yield after purification. This demonstrates that the acyltransferase enzyme (LovD) can tolerate the lack of a methyl group at the C-6 position of monacolin J 9. In a separate experiment ML-236C, the 6-desmethyl analogue of monacolin L 8, was added to cultures of the A. terreus lovC mutant. However, no compactin 3 could be detected by HPLC in the extract of the culture broth. This result suggests that either the enzyme responsible for hydroxylation at C-8 has a stringent requirement for the C-6 methyl group, or that 8 and ML-236C are not intermediates on the biochemical route to 1 and 3, respectively. The latter possibility may be more probable, as occurrence of 8 on the direct lovastatin biosynthetic pathway has been disputed and is still uncertain.10
To help determine if the A. terreus lovC disruptant could be used effectively to make dihydrolovastatin analogues, possible biotransformation of dihydromonacolin J 12 was examined. Compound 12 could be synthesised in 4 steps from 1 as shown in Scheme 2. Basic hydrolysis of 1 gave 9, which could be selectively protected with TBDMSCl in DMF to afford 10. Selective hydrogenation of 10 using Ir(cod)py(Pcy3)PF6 catalyst11 in MeOH generated 11 in 86% yield. Removal of the protecting group with buffered TBAF produced 12 in 34% overall yield from 1. Intermediate 11 could also be acylated with (S)-2-methylbutyric anhydride12 yielding 13 which, with subsequent removal of the protecting group, affords the target dihydrolovastatin 14 in 35% overall yield from 1.13 Compound 12 was added to cultures of the A. terreus lovC disruptant, but formation of 14 could not be detected by extensive HPLC analysis of the culture broth using synthetic 14 as a standard. Dihydrolovastatin 14 has been previously isolated from the fermentations of wild type A. terreus in 8% yield relative to lovastatin 1, as determined by HPLC.14 This earlier study in combination with the current results suggests that either disruption of lovC unexpectedly alters the capability of the organism to transform 12 to 14, or that this conversion does occur, but with alteration of the metabolism which further transforms 14 and brings its concentration below our detection limit.
![]() | ||
Scheme 2 Syntheses of dihydromonacolin J 12 and dihydrolovastatin 14. |
To verify that the post-PKS enzyme system required to oxidatively introduce the second double bond of the diene moiety is intact in the A. terreus lovC mutant, dihydromonacolin L 5 (isolated from A. nidulans lovB + lovC) was added to a fermentation of this organism and the broth extract was examined by HPLC for the presence of 1. Precursor 5 was transformed into 1 in 40% isolated yield, thereby demonstrating that all the necessary post-PKS steps for lovastatin biosynthesis are present in this mutant (Scheme 3).
![]() | ||
Scheme 3 A. terreus lovC biotransformations. |
The substrate specificity of the post-PKS machinery could be further tested by attempted transformation of a dihydromonacolin L derivative 16 having an unsaturation in the upper ring (Scheme 4). Elimination from the methanesulfonates of 5 or 1 gave α,β-dehydrodihydromonacolin L 16 and α,β-dehydrolovastatin 17, respectively.15 Addition of 15 to cultures of the A. terreus lovC disruptant followed after 10 hours by HPLC analysis of the culture showed no detectable trace of 17, suggesting that changes in the upper ring are not tolerated. The results of successful biotransformation experiments with A. terreus lovC mutant are summarised in Scheme 3.
![]() | ||
Scheme 4 Synthesis of unsaturated analogues. |
In order to determine the fate of 5, 14C-dihydromonacolin L (produced by addition of sodium 14C-acetate to A. nidulans lovB + lovC cultures), was fed to cultures of A. terreus lovA mutant. The extract of the culture was fractioned by thin layer chromatography, and the band containing most of the radioactivity was isolated to yield a chromatographically homogeneous compound. Full structural assignment reveals that 20 is the major product of 5 in the A. terreus lovA disruptant. This compound presumably arises as a result of two cycles of β-oxidation,16 first yielding the octaketide 18 followed by the heptaketide 19. This is then terminated by a P450 type hydroxylation at C-6 to produce 20 (Scheme 5). This process for metabolising 5 does not appear to be unique to the A. terreus lovA mutant, as 20 was also isolated from extracts of the cultures of A. nidulans lovB + lovC, along with a small amount of the intermediate heptaketide 19. Careful examination of the radioactive 5 obtained from this A. nidulans strain and used as the precursor for the biotransformation confirmed that it was not contaminated by 19 or 20. Since β-oxidation is ubiquitous in fungi such as Aspergillus,16 and hydroxylation at C-6 is common in the metabolism of lovastatin 1,1720 appears to arise from a widespread metabolic pathway in Aspergillus which is unrelated to lovastatin biosynthesis. Although this explains the lack of dihydromonacolin L 5 in the A. terreus lovA mutant cultures, it is perhaps surprising that blockage of a key oxidative enzyme on the route to lovastatin 1 should shunt the metabolism so completely.
![]() | ||
Scheme 5 Proposed pathway to 20. |
Another well established mode of reaction of P450 enzymes is the epoxidation of a double bond such as that present in 5.18 Hydroxylation with allylic rearrangement to directly form the proposed intermediate, α-hydroxy-3,5-dihydromonacolin L19 (Scheme 1), would actually be an unexpected reaction for this type of enzyme,20 which alternatively may be capable of dehydrogenation of 5 directly to the diene system. In order to determine if the LovA enzyme could form an epoxide during biosynthesis of lovastatin, the two diastereomeric epoxides 21a and 21b were prepared from 5 by treatment with MCPBA, followed by separation of the stereoisomers by HPLC (Scheme 6). The stereochemical assignment of the two epoxides was confirmed by X-ray crystallography of the α-isomer (Fig. 2). In a separate experiment, 14C labelled 5 was used in the synthesis so that the transformation of 21a and 21b could be followed by tracer analysis. Each 14C-labelled diastereomer was fed to separate cultures of A. terreus lovA mutant, which were subsequently analysed by thin layer chromatography with radioisotopic scanning (radio-TLC). If an epoxide were the product of the LovA enzyme and therefore a true intermediate on the pathway to lovastatin, then either 21a or 21b should presumably be converted through the rest of the post-PKS pathway to yield 1. However, no radioactive 1 could be detected by radio-TLC analysis. Analogous experiments wherein 21a and 21b were fed separately to cultures of A. terreus lovC mutant, yielded similar results: no radioactive 1 could be detected. In all cases, none of the original epoxide could be detected or recovered. Control experiments show that the epoxides are quite sensitive to the culture media, and decompose to complex mixtures of polar compounds that are not easily extracted into organic solvents. Treatment of 21a with the methyl ester of glycine results in rapid nucleophilic opening of the epoxide ring by the amino group (data not shown). Hence, it is likely that these epoxides can react with nucleophiles either in the media or in the fungal cells prior to exposure to post-PKS enzymes in the lovastatin pathway. Further experiments to determine the intermediacy of 21a or 21b will require purified enzymes.
![]() | ||
Scheme 6 Synthesis of 21a and 21b. |
To verify that the late stages of the post-PKS machinery are still functional in the A. terreus lovA mutant, monacolin J 9 was added to cultures of this organism. Examination of the extracts by HPLC allowed isolation of a trace amount (ca. 1%) of lovastatin 1 along with an additional metabolite. The latter was identified as 22. Similar to the fate of 5, compound 9 is primarily metabolised by β-oxidation enzymes to a truncated product. However in this case, the additional double bond in the decalin system appears to hinder hydroxylation at C-6. The biotransformations performed by A. terreus lovA mutant are summarised in Scheme 7.
![]() | ||
Scheme 7 Transformations by A. terreus lovA mutant. |
The mutant of A. terreus disrupted at the lovA gene displays quite different characteristics. In contrast to the lovC mutant, its β-oxidation system is highly active, with the consequence that there is rapid degradation of exogenously-added nonaketides which are known to be intermediates on the biosynthetic route to lovastatin 1. For example, only a small amount of monacolin J 9, the immediate precursor of 1, is converted into the target drug, with most of the added compound being oxidatively degraded to 22. This lovA mutant also does not accumulate dihydromonacolin L 5 as expected, but rather metabolises it rapidly to 20. The LovA protein, although resembling a P450 enzyme and clearly required for production of lovastatin 1, may also be involved in generating compounds which exercise control over expression or operation of the β-oxidation system in A. terreus.
Preparative HPLC was performed on a RANIN Dynamax high performance liquid chromatograph employing a manual injector, fraction collector and single wavelength detector. Reversed phase HPLC was conducted utilizing a Waters radial compression module with a Bondapak C18 25 × 100 mm column (15–20 µm particle size) with a guard column of similar packing. The mobile phase for RP-HPLC typically consisted of 100% H2O to 70% CH3CN–30% H2O over 25 min, linear gradient. Normal phase HPLC was done on the same system using a Waters radial compression Porasil silica gel column (125 Å, 25 × 100 mm). The NP-HPLC mobile phase employed was 30% EtOAc–70% hexane to 70% EtOAc–30% hexane over 27 min.
NMR spectra were recorded on a Varian Inova 600, Inova 300 or Unity 500 spectrometer. For 1H (300, 500 or 600 MHz) δ values are referenced to CHCl3 (7.24 ppm) and for 13C (125.8 or 150.9 MHz) referenced to CDCl3 (77.0 ppm).
Melting points are uncorrected and were determined on a Kauffman Block microscope or a Thomas-Hoover apparatus using open capillary tubes. Optical rotations were measured on a Perkin-Elmer 241 polarimeter with a micro cell (100 mm path length, 1 mL). IR spectra were recorded on a Nicolet Magna-IR 750 with a Nic-Plan microscope FT-IR spectrometer. Mass spectra were recorded on a Krator AEI MS–50 (HREIMS) and a ZabSpec Isomass VG (HRESMS).
Radioactivity was determined using standard liquid scintillation procedures in plastic 10 ml scintillation vials with a Beckman Ready-gel scintillation cocktail. The scintillation counter used was a Beckman LS 5000TD with automatic quench control to directly determine decompositions per minute (dpm) in the labelled samples against a quench curve prepared from Beckman 14C quenched standards. Radiolabelled compounds were also detected by a TLC assay, using a Berthold LB2760 2D-TLC scanner.
Aspergillus nidulans growth media was prepared by dissolving 20 g of glucose, 20 g of yeast extract, 1 g of peptone and 1 mL of a 1 mg per mL solution of p-aminobenzoic acid in 1 L of distilled deionized water. Aspergillus nidulans production media was prepared by dissolving in 1 L of distilled deionized water 1 mL trace element solution (1.0 g FeSO4·7H2O, 8.8 g ZnSO4·7H2O, 0.4 g CuSO4·5H2O, 0.15 g MnSO4·4H2O, 0.1 g Na2B7O7·10H2O, 0.05 g (NH4)6Mo7O24·4H2O, 0.5 mL conc. HCl dissolved in 1 L H2O), 100 mL of 10 × AMM (Aspergillus Minimal Media) salts (60 g NaNO3, 5.2 g KCl, 15.2 g KH2PO4 dissolved in 1 L of H2O and adjusted to pH 6.5), 1 mL of a 1 mg per mL p-aminobenzoic acid solution, and 0.9 mL of cyclopentanone and autoclaving. After cooling to room temperature 2.5 mL of a sterile solution of 20% MgSO4·7H2O and 25 mL of a sterile 40% lactose solution was added to the above flask. All biological media solutions and equipment were autoclaved at 121 °C and 15 psi of steam pressure for 15 min.
14C-4a,5-Dihydromonacolin L 5 was produced from 1 L of A. nidulans production culture fermented as described above, except that 250 µCi of sodium [1-14C]acetate (fed as a 5 mL aqueous solution 4 times per day) was added in addition to the unlabelled sodium acetate. The culture was harvested and extracted as above and the crude extract (97 mg) was fractionated by preparative TLC to give 22.5 mg of pure 14C-4a,5-dihydromonacolin L 5 with a specific activity of 0.185 µCi mg−1. The 1H NMR of the 14C-4a,5-dihydromonacolin L 5 was identical to that of the unlabelled compound.
For unlabelled 5: mp 162–163°C, lit. mp 163–164 °C;21 [α]25D = + 115 (c 0.22, methanol), lit. [α]25D = + 123.9 (c 0.5, methanol); UV (MeCN solution) λmax 228 nm (br 210–234); IR (microscope) 3391 (br m), 3018 (w), 2910 (s), 1713 (s), 1254 (s), 1062 (s), 1047 (s) cm−1; HREIMS 306.21902 (306.21948 calcd. for C19H30O3) (M+, 27%), 288.20876 (M − H2O, 18%), 161.13299 (M − C7H13O3, 100%), 105.07044 (C8H9+, 99%). 1H NMR (600 MHz, CDCl3) δ 5.57 (ddd, 1H, J = 9.8, 4.9, 2.7 Hz, H-3), 5.28 (d, 1H, J = 9.8 Hz, H-4), 4.67 (m, 1H, H-11), 4.38 (m, 1H, H-13), 2.72 (dd, 1H, J = 17.6, 5.13 Hz, H-14), 2.60 (ddd, 1H, J = 17.6, 3.7, 1.6 Hz, H-14), 2.21 (m, 1H, H-2), 2.00 (m, 1H, H-6), 1.95 (m, 1H, H-12), 1.89 (m, 1H, H-4a), 1.81–1.73 (m, 2H, H-10 and H-12), 1.62 (m, 2H, H-9), 1.58–1.42 (m, 5H, H-5, H-7, H-8a and H-10), 1.07 (dq, 1H, J = 11.9, 3.7 Hz, H-8), 0.97 (dq, 1H, J = 11.9, 3.0 Hz, H-8), 0.96 (d, 3H, J = 7.3 Hz, 6-CH3), 0.82 (d, 3H, J = 6.9 Hz, 2-CH3); 13C NMR (125 MHz, CDCl3) δ 170.4 (C-15), 132.6 (C-3), 131.6 (C-4), 76.1 (C-11), 62.8 (C-13), 41.4 (C-8a), 40.0 (C-8), 38.9 (C-5), 38.7 (C-14), 37.3 (C-4a), 36.1 (C-12), 33.2 (C-10), 32.3 (C-7), 32.0 (C-2), 27.5 (C-6), 23.7 (C-1), 23.6 (C-9), 18.2 (6-CH3), 14.9 (2-CH3).
[α]25D = +17.3 (c 0.14, CH3OH); IR (microscope) 3236 (br s), 2927 (s), 2879 (s), 1707 (m), 1645 (m), 1451 (s), 1318 (s), 1093 (s), 1075 (s), 1060 (s), 1049 (s), 1026 (s), 973 (s), 858 (s) cm−1; HREIMS [M]+ 320.19827 (320.19876 calcd. for C19H28O4) 320.2 (2%), 302.2 (9%), 198.1 (58%), 157.1 (100%), 105.1 (41%); 1H NMR (500 MHz, CD3OD) δ 5.93 (d, 1H, J = 10.0 Hz, H-4), 5.75 (dd, 1H, J = 10.0, 6.2 Hz, H-3), 5.45 (br s, 1H, H-5), 4.23 (br dd, 1H, J = 6.5, 2.8 Hz, H-8), 9.92 (m, 1H, H-11), 3.79 (m, 1H, H-11), 3.79 (m, 1H, H-11), 3.79 (m, 1H, H-13), 3.68 (br t, 2H, J = 6.5 Hz, H-14), 2.38 (m, 2H, H-2, H-6), 2.13 (br dd, 1H, J = 12.1, 2.8 Hz, H-13), 1.92–1.68 (m, 4H, H-7, Ha-9, Ha-12), 1.67–1.50 (m, 3H, H-1, Ha-10, Hb-12), 1.41 (m, 1H, Hb-10), 1.31 (m, 1H, H-9), 1.18 (d, 3H, J = 7.4 Hz, 6-Me), 0.89 (d, 3H, J = 6.9 Hz, 2-Me); 13C NMR (125 MHz, CD3OD) δ 190.0 (C-15), 134.1 (C-4), 133.2 (C-4a), 130.6 (C-3) 130.0 (C-5), 71.7 (C-8), 69.2 (C-11), 65. 9 (C-13), 60.1 (C-14), 45.4 (C-7), 41.0 (C-10), 39.8 (C-8a), 37.6 (C-1), 37.1 (C-12), 35.6 (C-9), 32.1, 29.1 (C-2, C-6), 23.65 (6-Me), 14.3 (2-Me).
[α]25D = −10.1 (c 1.35, CH2Cl2); FTIR (cast) 3446 (br), 2954 (s), 1734 (s), 1254 (s), 1082 (s), 735(s) cm−1; HREIMS [M]+ 434.28466 (434.28525 calcd. for C25H42O4Si), 434.3 (7%), 359.2 (17%), 284.2 (24%), 159.1 (100%), 101.0 (59%); 1H NMR (600 MHz, CDCl3) δ 5.95 (d, 1H, J = 9.5 Hz), 5.77 (dd, 1H, J = 6, 9.5 Hz), 5.52 (s, 1H), 4.65 (m, 1H), 4.27 (q, 1H, J = 3.5 Hz), 4.21 (s, 1H), 2.58 (dd, 1H, J = 17.5, 4 Hz), 2.53 (ddd, 1H, J = 17.5, 3, 1.5 Hz), 2.42 (m, 1H), 2.35 (s, 1H, J = 6.5), 2.14 (dd, 1H, J = 12, 2.5 Hz), 1.91–1.72 (m, 6H), 1.69 (ddd, 1H, J = 15, 3 Hz), 1.45 (m, 2H), 1.17 (d, 3H, J = 7.5 Hz), 0.88 (d, 3H, J = 7 Hz), 0.86 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 170.5, 133.7, 131.3, 130.0, 128.4, 76.5, 65.3, 63.5, 39.3, 38.8, 36.9, 36.5, 35.8, 33.0, 30.8, 27.4, 25.7, 24.3, 23.8, 18.0, 14.0, −4.8, −4.9.
[α]25D = +76 (c 1.20, CH2Cl2); FTIR (cast) 3463 (br), 1733 (s), 1253 (s) cm−1; HREIMS [M]+ 436.30047 (436.30090 calcd. for C25H44O4Si) 436 (1%), 418 (6%), 361 (28%), 343 (8%) and 75 (100%); 1H NMR (300 MHz, CDCl3) δ 5.61 (ddd, 1H, J = 9.7, 4.9, 2.6 Hz), 5.36 (d, 1H, J = 9.8 Hz), 4.66 (m, 1H,), 4.27 (m, 1H), 4.16 (m, 1H), 2.59 (dd, 1H, J = 17.5, 4.3 Hz), 2.56 (ddd, 1H, J = 17.5, 3.5, 1.4 Hz), 2.52–1.01 (m, 20H), 1.19 (d, 1H, J = 7.4 Hz), 0.87 (m, 9H), 0.81 (d, 3H, J = 7.1 Hz), 0.06 (3 H, s) and 0.05 (3 H, s); 13C NMR (125 MHz, CDCl3) δ 174.0, 170.3, 132.6, 131.0, 76.3, 69.8, 63.6, 41.8, 41.7, 39.3, 38.6, 37.6, 36.8, 35.6, 33.2, 31.3, 30.9, 26.7, 26.7, 25.7, 23.1, 21.0, 16.5, 14.9, 11.7, −4.8, −4.9.
[α]25D = +137.4 (c 0.38, MeOH); FTIR (cast), 3361 (br), 2906 (s), 1703 (s), 1259 (s), 1039 (s) cm−1; HREIMS [M]+ 322.21394 (322.2144 calcd. for C19H30O4) 322.2 (1%), 286.2 (10%), 200.1 (18%), 159.1 (79%), 105.1 (100%); 1H NMR (600 MHz, CDCl3) δ 5.60 (ddd, 1H, J = 9.7, 4.8, 2.6 Hz), 5.35 (d, 1H, J = 10.1 Hz), 4.68 (m, 1H), 4.36 (quintet, 1H, J = 3.7 Hz), 4.14 (d, 1H, J = 2.8 Hz), 2.71 (dd, 1H, J = 18.0, 5.1 Hz), 2.60 (ddd, 1H, J = 18.0, 3.8, 1.8 Hz), 2.01–1.90 (m, 3H), 1.82–1.20 (m, 16 H), 1.18 (d, 3H, J = 7.5 Hz), 0.83 (d, 3H, J = 7.0 Hz); 13C NMR (150 MHz, CDCl3) δ 170.4, 132.3, 131.5, 76.1, 67.1, 62.8, 42.7, 39.3, 39.0, 38.6, 37.0, 36.3, 32.8, 31.4, 29.7, 27.0, 23.0, 21.6, 15.0.
[α]25D = +73 (c 0.20, CHCl3); FTIR (cast) 2295 (s), 1727 (s), 1253 (s), 1079 (s) cm−1; 1H NMR (600 MHz, CDCl3) δ 5.62 (ddd, 1H, J = 9.5, 4.5, 2.5 Hz), 5.36 (d, 1H, J = 9.5 Hz), 5.15 (d, 1H, J = 2.5 Hz), 4.55 (m, 1H), 4.25 (quintet, 1H, J = 3.5 Hz), 2.57 (dd, 1H, J = 17, 4.5 Hz), 2.52 (dd, 1H, J = 17, 1 Hz), 2.45 (m, 1H), 2.41 (m, 1H), 2.32 (q, 1H, J = 7 Hz), 2.27 (m, 1H), 2.02 (m, 1H), 1.89 (d, 1H, J = 15 Hz), 1.83–1.80 (m, 2H), 1.72–1.44 (m, 5H), 1.32–1.22 (m, 2H), 1.17 (d, 2H, J = 7 Hz), 1.10 (d, 3H, J = 7 Hz), 1.07 (d, 3H, J = 7.5 Hz), 0.93 (t, 3H, J = 7.5 Hz), 0.86 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 175.0, 170.1, 132.6, 131.0, 76.3, 69.8, 63.6, 41.8, 41.7, 39.3, 38.6, 37.6, 36.8, 35.6, 33.2, 31.3, 30.9, 26.8, 26.7, 26.6, 25.6, 23.1, 21.0, 17.9, 16.5, 16.4, 14.9, 11.7, −4.8, −4.9.
1H NMR (300 MHz, CDCl3) δ 5.62 (m, 1H), 5.35 (d, 1H, J = 9.6 Hz), 5.17 (m, 1H), 4.55 (m, 1H), 4.35 (m, 1H), 2.74 (d, 1H, J = 5.0 Hz), 2.68 (d, 1H, J = 5.0 Hz), 2.61 (dd, 1H, J = 3.8, 1.5 Hz), 2.52 (dd, 1H, J = 4.2, 1.5 Hz), 2.43 (d, 1H, J = 6.0 Hz), 2.4–2.2 (m, 2H), 2.05–1.75 (m, 6H), 1.70–1.40 (m, 10H), 1.15 (d, 3H, J = 7.0 Hz), 1.08 (d, 3H, J = 7.4 Hz), 0.88 (t, 3H, J = 8 Hz), 0.82 (d, 3H, J = 7.0 Hz).
[α]25D = +78 (c 0.15, CHCl3); FTIR (cast) 3407 (br s), 2928 (s), 1710 (s), 1256 (s), 1075 (s), 754 (s); HREIMS [M]+ 306.18245 (306.18311 calcd. for C18H26O4); 1H NMR (500 MHz, CDCl3) δ 5.92 (d, 1H, J = 9.6 Hz), 5.71 (dd, 1H, J = 9.6, 6.0 Hz), 5.52 (br d, 1H, J = 2.1 Hz), 4.69 (m, 1H), 4.52 (m, 1H), 4.21 (br s, 1H), 2.67 (dd, 1H, J = 17.7, 5.0 Hz), 2.59 (ddd, 1H, J = 17.7, 3.7, 1.7 Hz), 2.31 (m, 2H), 2.14 (m, 2H), 1.96 (m, 2H), 1.82–1.62 (m, 5H), 1.53–1.39 (m, 2H), 0.88 (d, 3H, J = 7.0 Hz); 13C NMR (75 MHZ, CDCl3) δ 170.8, 133.3, 133.0, 128.3, 123.6, 76.2, 64.4, 62.6, 38.8, 38.5, 36.4, 36.1, 32.6, 30.8, 29.1, 23.8, 20.3, 13.9.
[α]25D = +8.6 (c 1.00, CH2Cl2); FTIR (cast) 2915 (s), 1717 (s), 1389 (s), 1248 (s), 818 (s) cm−1; HREIMS [M]+ 288.20866 (288.20892 calcd. for C19H28O2) (19%), 273.2 (17%), 228.2 (22%), 176.1 (85%), 161.1 (71%), 105.1 (100%); 1H NMR (600 MHz, CDCl3) δ 6.85 (ddd, 1H, J = 9.5, 9.5, 4.4 Hz), 6.00 (d, 1H, J = 9.8 Hz), 5.57 (ddd, 1H, J = 9.7, 4.7, 2.8 Hz), 5.28 (d, 1H, J = 9.8 Hz), 4.41 (dddd, 1H, J = 12.3, 12.3, 7.6, 4.7 Hz), 2.33 (m, 2H), 2.21 (m, 1H), 2.11 (m, 1H), 1.91–1.87 (m, 2H), 1.62–1.41 (m, 8H), 1.34–1.22 (m, 2H), 1.08 (m, 1H), 0.99 (dd, 1H, J = 10.3, 2.6 Hz), 0.96 (d, 3H, J = 7.3 Hz), 0.83 (d, 3H, J = 7.0); 13C NMR (150 MHz, CDCl3) δ 164.3, 144.8, 132.5, 131.6, 121.3, 78.0, 41.1, 39.6, 38.3, 38.2, 37.0, 32.0, 31.8, 31.5, 29.0, 27.1, 23.2, 17.7, 14.6.
[α]25D = +136.4 (c 3.30, CH2Cl2); FTIR (cast) 2963 (s), 1723 (s), 1383 (s), 1247 (s), 818 (s) cm−1; HREIMS [M]+ 386.24530 (386.24570 calcd. for C24H34O4) 386.2 (2%), 284.2 (17%), 198.1 (64%), 159.1 (100%); 1H NMR (600 MHz, CDCl3) δ 6.83 (ddd, 1H, J = 9.8, 6.1, 2.4 Hz), 5.98 (ddd, 1H, J = 9.7, 2.6, 0.9 Hz), 5.97 (d, 1H, J = 10.5 Hz), 5.76 (dd, 1H, J = 9.5, 6.1 Hz), 5.50 (m, 1H), 5.36 (d, 1H, J = 3.2 Hz), 4.31 (dddd, 1H, J = 11.5, 11.5, 5.3, 3.5 Hz), 2.42 (m, 1H), 2.37–2.30 (m, 3H), 2.25–2.19 (m, 2H), 1.96–1.87 (m, 3H), 1.69–1.59 (m, 3H), 1.51–1.28 (m, 4H), 1.08 (d, 3H, J = 7.0 Hz), 1.05 (d, 3H, J = 7.4 Hz), 0.87 (d, 3H, J = 7.0 Hz), 0.85 (t, 3H, J = 7.5 Hz); 13C NMR (125 MHz, CDCl3) δ 176.6, 164.2, 144.7, 133.0, 131.6, 129.7, 128.3, 121.5, 78.5, 67.7, 41.4, 37.3, 36.6, 32.7, 32.4, 30.7, 29.5, 27.4, 26.8, 24.2, 22.8, 16.2, 13.8, 11.7.
[α]20D +120.3 (c 0.10, CHCl3); FTIR (cast) 3020, 2952, 2915, 2860, 1696, 1445, 1411, 1377, 1310, 1297, 1267, 1238, 1211, 720 cm−1; HREIMS [M]+ 236.1777 (236.1776 calcd. for C15H24O2); 1H NMR (500 MHz, CDCl3) δ 5.57 (ddd, 1H, J = 10.0, 5.0, 3.0 Hz), 5.28 (d, 1H, J = 10.0 Hz), 2.42 (ddd, 1H, J = 15.5, 10.0, 5.0 Hz), 2.26–2.19 (m, 2H), 2.00 (m, 1H), 1.96–1.97 (m, 2H), 1.60–1.44 (m, 5H), 1.36 (m, 1H), 1.25 (dt, 1H, J = 13.0, 4.5 Hz), 1.10 (dq, 1H, J = 12.0, 4.0 Hz), 1.02–0.94 (m, 1H), 0.96 (d, 3H, J = 7.5 Hz), 0.82 (d, 3H, J = 7.0 Hz); 13C NMR (125 MHz, CDCl3) δ 179.9, 132.3, 131.5, 41.0, 39.9, 38.9, 37.3, 32.3, 32.0, 31.9, 27.5, 23.8, 23.6, 18.2, 15.0.
This same product could be isolated from the CH2Cl2 extract of A. nidulans lovB + lovC production cultures grown as described above. A portion (23.2 mg) of the crude CH2Cl2 extract was treated with CH2N2 (Et2O solution) to give 26.1 mg crude methylated product which was fractionated by HPLC to give 2.2 mg pure β-oxidation product 20.
FTIR (cast) 3297 (br), 3008 (s), 1737 (s), 1437 (m), 1223 (s), 1170 (s) cm−1; HREIMS 248.17729 (248.1763 calcd. for C16H24O2) [M − H2O]+, 217.1 (18%), 192.1 (14%), 161.1 (100%), 119.1 (52%), 105.1 (78%); 1H NMR (600 MHz, CDCl3) δ 5.58 (ddd, 1H, J = 9.5, 4.5, 2.5 Hz, H-3), 5.30 (d, 1H, J = 9.5 Hz, H-4), 3.65, (s, 3H, OCH3), 2.37 (ddd, 1H, J = 15, 10, 5 Hz, H-10a/b), 2.24 (m, 1H, H-2), 2.18 (ddd, 1H, J = 15, 9.5, 6.5 Hz, H-10a/b), 1.89 (m, 2H, H-9), 1.80, 1.78 (d, 1H, J = 2.5, H-4a), 1.69, 1.67, 1.47, 1.23 (s, 3H, 6-CH3), 1.02, 0.83 (d, 3H, J = 7 Hz, 2-CH3); 13C NMR (125 MHz, CDCl3) δ 171.3, 132.9, 130.3, 71.2, 51.6, 47.1, 41.1, 41.0, 40.8, 39.2, 32.0, 31.9, 27.0, 26.1, 24.3, 14.8.
For 4a,5-dihydromonacolin L α-epoxide 21a: [α]25D = +90 (c 0.95, CHCl3); FTIR (cast) 3392 (br), 2915 (s), 2876 (s), 1709 (s), 1257 (s), 1044 (s), 842 (s); HREIMS [M]+ 322.21451 (322.21442 calcd. for C19H30O4) 322 (5%), 307 (5%), 191 (48%), 179 (100%), 95 (65%); 1H NMR (500 MHz, CDCl3) δ 4.63 (dddd, 1H, J = 11.0, 11.0, 7.6, 3.8 Hz), 4.36 (m, 1H), 2.98 (d, 1H, J = 2.4 Hz), 2.72 (d, 1H, J = 3.7 Hz), 2.69 (d, 1H, J = 5.0 Hz), 2.61 (dd, 1H, J = 3.6, 1.7 Hz), 2.56 (dd, 1H, J = 3.7, 1.7 Hz), 2.30 (m, 1H), 2.05 (m, 2H), 1.93 (m, 2H), 1.8–1.6 (m, 2H), 1.6–1.3 (m, 10H), 0.95 (d, 3H, J = 7.1 Hz), 0.89 (d, 3H, J = 7.2 Hz); 13C NMR (125 MHz, CDCl3) δ 170.4, 76.0, 62.8, 58.8, 57.5, 38.6, 38.8, 37.4, 36.3, 36.2, 36.1, 33.0, 32.0, 30.3, 27.6, 23.9, 23.7, 18.1, 10.2.
For 4a,5-Dihydromonacolin L β-epoxide 21b: 1H MNR (600 MHz, CDCl3) δ 4.65 (dddd, 1H, J = 11.5, 11.5, 7.3, 4.0 Hz), 4.37 (m, 1H), 3.17, (dd, 1H, J = 3.9, 5.5 Hz), 2.91 (d, 1H, J = 3.9 Hz), 2.71 (dd, 1H, J = 17.6, 5.0 Hz), 2.60 (ddd, 1H, J = 17.6, 3.7, 1.7 Hz), 2.15 (m, 1H), 2.05 (m, 1H), 1.90 (m, 2H), 1.75 (m, 2H), 1.65–1.40 (m, 8H), 1.20 (m, 2H), 0.97 (d, 3H, J = 7.2 Hz), 0.92 (d, 3H, J = 7.1 Hz); 13C NMR (125 MHz, CDCl3) δ 170.2, 75.8, 62.8, 58.2, 57.0, 41.5, 38.6, 37.6, 35.9, 35.6, 34.6, 33.2, 31.7, 28.9, 26.9, 23.2, 22.7, 18.0, 9.5.
1H NMR (600 MHz, CDCl3) δ 5.95 (d, 1H, J = 10.0 Hz), 5.75 (dd, 1H, J = 9.1, 6.2 Hz), 5.55 (m, 1H), 4.28 (m, 1H), 3.68 (s, 3H), 2.50–2.20 (m, 6H), 1.80–1.20 (m, 10H), 1.16 (d, 3H, J = 7.4 Hz), 0.88 (d, 3H, J = 7.0 Hz).
Footnotes |
† The gene cluster for compactin 3 has recently been characterised (see ref. 8b). |
‡ For a detailed description of the construction of A. terreus disruptants and A. nidulans transformants see the supporting information for ref. 5. |
This journal is © The Royal Society of Chemistry 2003 |